Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study

[1]  Ewout Steyerberg,et al.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects , 2018, British Medical Journal.

[2]  J. Ioannidis,et al.  How often can meta-analyses of individual-level data individualize treatment? A meta-epidemiologic study. , 2018, International journal of epidemiology.

[3]  L. Mbuagbaw,et al.  Subgroup analyses are seldom possible and subgroup effects are rare in Cochrane HIV systematic reviews. , 2018, Journal of clinical epidemiology.

[4]  J. Ioannidis.  The Proposal to Lower P Value Thresholds to .005. , 2018, JAMA.

[5]  Comparison of nuisance parameters in pediatric versus adult randomized trials: a meta-epidemiologic empirical evaluation , 2018, BMC Medical Research Methodology.

[6]  Peter Tugwell,et al.  CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials , 2017, British Medical Journal.

[7]  P. Tugwell,et al.  Setting priorities for knowledge translation of Cochrane reviews for health equity: Evidence for Equity , 2017, International Journal for Equity in Health.

[8]  Kristin L. Sainani,et al.  Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials , 2017, JAMA internal medicine.

[9]  F. Song,et al.  Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine , 2016, BMC Medicine.

[10]  J. Ioannidis,et al.  Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses , 2016, British Medical Journal.

[11]  H. Krumholz,et al.  Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals , 2016, Trials.

[12]  Michelle Lemieux,et al.  Identifying and removing duplicate records from systematic review searches. , 2015, Journal of the Medical Library Association : JMLA.

[13]  S. Zhang,et al.  Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[15]  Peter Jüni,et al.  Systematic reviews and meta-analyses of randomized trials: principles and pitfalls , 2014 .

[16]  Thomas Agoritsas,et al.  How to use a subgroup analysis: users' guide to the medical literature. , 2014, JAMA.

[17]  P. Sedgwick.  Meta-analyses: heterogeneity and subgroup analysis , 2013 .

[18]  Michael Borenstein,et al.  Meta-Analysis and Subgroups , 2013, Prevention Science.

[19]  J. Ioannidis,et al.  Empirical Evaluation of Age Groups and Age-Subgroup Analyses in Pediatric Randomized Trials and Pediatric Meta-analyses , 2012, Pediatrics.

[20]  Denise Thomson,et al.  Standard 6: Age Groups for Pediatric Trials , 2012, Pediatrics.

[21]  Gordon H Guyatt,et al.  Credibility of claims of subgroup effects in randomised controlled trials: systematic review , 2012, BMJ : British Medical Journal.

[22]  W. Rodriguez,et al.  Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs , 2011, Pediatrics.

[23]  P. Wilson,et al.  Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia , 2011, Diabetes Care.

[24]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[25]  J. Ioannidis,et al.  Comparative effectiveness of medical interventions in adults versus children. , 2010, The Journal of pediatrics.

[26]  F. Collins,et al.  The path to personalized medicine. , 2010, The New England journal of medicine.

[27]  Xin Sun,et al.  Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses , 2010, BMJ : British Medical Journal.

[28]  Tony Tse,et al.  Reporting "basic results" in ClinicalTrials.gov. , 2009, Chest.

[29]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[30]  P. Jones,et al.  Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. , 2007, The Cochrane database of systematic reviews.

[31]  P. Jones,et al.  Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. , 2005, The Cochrane database of systematic reviews.

[32]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[33]  S. Pocock,et al.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.

[34]  R. Haynes,et al.  What kind of evidence is it that Evidence-Based Medicine advocates want health care providers and consumers to pay attention to? , 2002, BMC health services research.

[35]  P. Jones,et al.  Fluticasone versus beclomethasone or budesonide for chronic asthma. , 2000, The Cochrane database of systematic reviews.

[36]  D Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[37]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[38]  P. Jones,et al.  Budesonide at different doses for chronic asthma. , 2000, The Cochrane database of systematic reviews.

[39]  P. Brennan,et al.  Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial , 2000, BMJ : British Medical Journal.

[40]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[41]  D. Reda,et al.  Age-Race Subgroup Compared With Renin Profile as Predictors of Blood Pressure Response to Antihypertensive Therapy , 1998 .

[42]  R B Haynes,et al.  The Cochrane Collaboration-Advances and Challenges in Improving Evidence-based Decision Making , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  G H Guyatt,et al.  A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.

[44]  S. Pocock,et al.  Statistical problems in the reporting of clinical trials. A survey of three medical journals. , 1987, The New England journal of medicine.